Jpmorgan Chase & CO Janux Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 19,213 shares of JANX stock, worth $888,601. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,213

Previous 19,343 0.67%

Holding current value

$888,601

Previous $728,000 10.44%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$35.12 - $64.78 $4,565 - $8,421	-130 Reduced 0.67%	19,213 $804,000
Q1 2024 May 10, 2024	BUY	$7.93 - $49.75 $12,743 - $79,948	1,607 Added 9.06%	19,343 $728,000
Q4 2023 Feb 12, 2024	SELL	$5.85 - $11.7 $765,607 - $1.53 Million	-130,873 Reduced 88.07%	17,736 $190,000
Q3 2023 Nov 14, 2023	SELL	$9.56 - $14.0 $46,146 - $67,578	-4,827 Reduced 3.15%	148,609 $1.5 Million
Q2 2023 Aug 11, 2023	BUY	$11.08 - $15.92 $263,471 - $378,561	23,779 Added 18.34%	153,436 $1.82 Million
Q1 2023 May 18, 2023	BUY	$11.25 - $22.21 $147,892 - $291,972	13,146 Added 11.28%	129,657 $1.57 Million
Q1 2023 May 11, 2023	BUY	$11.25 - $22.21 $143,190 - $282,688	12,728 Added 12.26%	116,511 $1.41 Million
Q4 2022 Feb 13, 2023	SELL	$11.1 - $18.26 $14,097 - $23,190	-1,270 Reduced 1.21%	103,783 $1.37 Million
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $17,041 - $26,523	1,575 Added 1.52%	105,053 $1.42 Million
Q2 2022 Aug 11, 2022	BUY	$9.52 - $15.65 $814,455 - $1.34 Million	85,552 Added 477.25%	103,478 $1.26 Million
Q1 2022 May 11, 2022	BUY	$13.24 - $20.24 $61,407 - $93,873	4,638 Added 34.9%	17,926 $256,000
Q4 2021 Feb 10, 2022	BUY	$15.44 - $27.32 $105,208 - $186,158	6,814 Added 105.25%	13,288 $262,000
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $134,011 - $224,583	6,474 New	6,474 $140,000

Others Institutions Holding JANX

# of Institutions

161

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

103K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.93B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Janux Therapeutics, Inc. Transaction History